Study shows superiority of ViiV's long-acting cabotegravir over oral PrEP Truvada

8 July 2020

Specialty HIV company ViiV Healthcare, majority owned by GlaxoSmithKline (LES: GSK), has presented from the HIV Prevention Trials Network (HPTN) 083 study demonstrating the superior efficacy of investigational, long-acting, injectable cabotegravir administered every two months when compared to daily oral emtricitabine/tenofovir disoproxil fumarate 200mg and 300mg (FTC/TDF) tablets for HIV prevention.

HPTN 083 is a Phase IIb/III randomized, multicenter, double-blind, clinical trial that is evaluating the safety and efficacy of long-acting, injectable cabotegravir for HIV pre-exposure prophylaxis (PrEP) among men who have sex with men (MSM) and transgender women who have sex with men.

ViiV recently won approval from the Canadian medicines regulator for Cabenuva (cabotegravir/rilpivirine), the first and only once-monthly, complete long-acting regimen for the treatment of HIV-1 infection. The combo was developed in collaboration with Johnson & Johnson’s (NYSE: JNJ) pharma arm Janssen, the developer of rilpivirine, which markets the drug as Edurant.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK